FDA to Incentivize Faster Drug Approvals via New Staff Bonus Program
The U.S. Food and Drug Administration is implementing a performance-based bonus structure to reward staffers who complete drug reviews ahead of schedule. This initiative aims to accelerate the therapeutic pipeline but has sparked immediate debate over the potential impact on safety standards and regulatory rigor.